MAPT and Alzheimer disease: To characterise the phosphorylation profiles of the tau species enriched by co-IP using different pTau-targeting antibodies, we compared the abundance of phosphorylated tau residues identified after co-IP of pT217 and pT231 and pS396/S404 (PHF1) in the same 10 cases of advanced AD (Supplementary Table 9).